분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-04-10 08:47:08 , Hit : 442
 Nature Methods retracts CRISPR study

Biocentury

https://www.biocentury.com/bc-extra/preclinical-news/2018-03-30/nature-methods-retracts-crispr-study

6:47 am JST  |  Mar 31, 2018  |  BC Extra  |  Preclinical News
by Allison Johnson


On Friday, Nature Methods retracted a 2017 CRISPR-Cas9 gene editing letter days after the paper's authors walked back on their findings in an expanded study published in the preprint journal bioRxiv.

The 2017 Nature Methods paper from researchers at Stanford University, Columbia University and University of Iowa claimed CRISPR gene editing led to an unexpected high level of off-target mutations. In the retraction, the journal said there were insufficient data to support the claim and cited the need for a control comparison between parent and offspring mice to determine whether natural genetic variation clouded the authors' interpretation of CRISPR-mediated off-target mutations (see BioCentury Extra, May 30, 2017).

The journal said two of the six study authors agreed with the retraction, and four did not. It did not provide the authors’ reasoning.

The findings of the group's expanded bioRxiv study, which used two mouse strains with different genetic backgrounds, suggested CRISPR editing may not introduce numerous and unintended mutations (see BioCentury Extra, March 26).

Others, including executives at Editas Medicine Inc. (NASDAQ:EDIT) and Editas advisor George Church, have published studies showing that natural genetic variations prior to CRISPR treatment were likely the cause of observed variants (see BioCentury Extra, June 22, 2017).

Based on public responses to the original Nature Methods study, the journal published an editorial note in June stating the conclusions of the paper "are subject to criticisms that are being considered by editors," and issued an editorial expression of concern in July (see BioCentury Extra, June 16, 2017).

Stanford professor Vinit Mahajan, a corresponding author on the Nature Methods paper, told BioCentury his group is using whole genome sequencing on additional CRISPR treated mice to elucidate CRISPR's off-target effects.








1238   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 154
1237   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 143
1236   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 144
1235   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 223
1234   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 235
  Nature Methods retracts CRISPR study  이성욱 2018/04/10 442
1232   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 270
1231   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 280
1230   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 466
1229   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 366
1228   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 454
1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 447
1226   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 414
1225   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 361
1224   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 363
1223   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 338
1222   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 367
1221   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 341
1220   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 245
1219   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 330

[1] 2 [3][4][5][6][7][8][9][10]..[63] [다음 10개]
 

Copyright 1999-2018 Zeroboard / skin by ROBIN